Abstract
We identified a duplication of the MYB oncogene in 8.4% of individuals with T cell acute lymphoblastic leukemia (T-ALL) and in five T-ALL cell lines. The duplication is associated with a threefold increase in MYB expression, and knockdown of MYB expression initiates T cell differentiation. Our results identify duplication of MYB as an oncogenic event and suggest that MYB could be a therapeutic target in human T-ALL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Pui, C.H. et al. N. Engl. J. Med. 350, 1535–1548 (2004).
Grabher, C. et al. Nat. Rev. Cancer 6, 347–359 (2006).
De Keersmaecker, K. et al. Haematologica 90, 1116–1127 (2005).
Weng, A.P. et al. Science 306, 269–271 (2004).
Graux, C. et al. Nat. Genet. 36, 1084–1089 (2004).
Speicher, M.R. & Carter, N.P. Nat. Rev. Genet. 6, 782–792 (2005).
Iafrate, A.J. et al. Nat. Genet. 36, 949–951 (2004).
Redon, R. et al. Nature 444, 444–454 (2006).
Bender, T.P. et al. Nat. Immunol. 5, 721–729 (2004).
Rothenberg, E.V. & Taghon, T. Annu. Rev. Immunol. 23, 601–649 (2005).
Hess, J.L. et al. Blood 108, 297–304 (2006).
Sakamoto, H. et al. Blood 108, 896–903 (2006).
Lund, A.H. et al. Nat. Genet. 32, 160–165 (2002).
Suzuki, T. et al. Nat. Genet. 32, 166–174 (2002).
Acknowledgements
This work was supported by grants from the Foundation Against Cancer (a public interest foundation) (J.C.), the Fonds voor Wetenschappelijk Onderzoek (FWO)-Vlaanderen (P.M., F.S.), the Interuniversity Attraction Poles granted by the Belgian Federal Office for Scientific, Technical and Cultural Affairs, a José Carreras fellowship from the European Hematology Association (J.C.), Concerted Research Action grant 12051203 (F.S.), the Sophia Foundation for Medical Research (SSWO-404, P.V.V.), the Spanish Association Against Cancer (I.L., M.D.O.) and a Concerted Research Action Grant from K.U. Leuven (J.C., P.V., I.W., P.M.). I.L. is a visiting postdoctoral researcher, K.D.K. is an aspirant, J.C. is a postdoctoral researcher and P.V. is a clinical investigator of the FWO-Vlaanderen. M.B. is funded by the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT-Vlaanderen).
Author information
Authors and Affiliations
Contributions
I.L., K.D.K., P.V.V., J.P.P.M. and J.C. designed the study; I.L., K.D.K., P.V.V., C.G., B.C., N.M., I.W. and J.P.P.M. performed experiments and data analysis; C.G., F.L., H.B.B., R.P., F.S., M.D.O., M.B., G.F., P.V. and J.P.P.M. provided material and I.L., K.D.K., P.V.V., J.P.P.M., P.M., P.V., I.W. and J.C. contributed to writing of the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Fig. 1
FISH detects MYB duplication. (PDF 862 kb)
Supplementary Table 1
Copy number of MYB and flanking genes in individuals and cell lines with MYB duplication. (PDF 139 kb)
Supplementary Table 2
Cytogenetic and molecular characteristics of individuals with T-ALL with MYB duplication. (PDF 119 kb)
Rights and permissions
About this article
Cite this article
Lahortiga, I., De Keersmaecker, K., Van Vlierberghe, P. et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet 39, 593–595 (2007). https://doi.org/10.1038/ng2025
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng2025
This article is cited by
-
Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia
Oncogene (2024)
-
Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML
Cell Death & Disease (2023)
-
Regulation of MYB by distal enhancer elements in human myeloid leukemia
Cell Death & Disease (2021)
-
MYB oncoproteins: emerging players and potential therapeutic targets in human cancer
Oncogenesis (2021)
-
C/EBPβ is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia
Oncogene (2021)